The Board of Directors of Dishman Carbogen Amcis will convene on August 12, 2026, to consider a proposal for raising capital through the issuance of Non-Convertible Debentures (NCDs). The company intends to execute this fundraising via private placement, a move that signals its intent to strengthen its capital structure or fund specific corporate initiatives without diluting equity ownership. The final approval for the issuance remains subject to requisite regulatory and statutory clearances.

Board Meeting Details

The meeting is scheduled for Wednesday, August 12, 2026. Pursuant to Regulations 29 and 50 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has intimated the stock exchanges regarding the agenda item. The primary objective of this specific agenda point is to seek board approval for the debt instrument issuance.

Regulatory Compliance

The disclosure was made in compliance with SEBI’s listing regulations, ensuring timely communication to investors and market participants. The company stated that the proposal is subject to such regulatory or statutory approvals as may be required. This standard clause indicates that while the board may approve the principle of the issue, the actual execution depends on external regulatory sign-offs and market conditions at the time of issuance.

Shrima Gaurangbhai Dave, Company Secretary, signed the intimation letter dated August 7, 2026. The notice was addressed to the Department of Corporate Services at BSE Ltd. and the Listing Department at National Stock Exchange of India Ltd., confirming the dual-listed status of the entity.

Dishman Carbogen Amcis Ltd’s wholly-owned subsidiary, CARBOGEN AMCIS AG, has successfully commissioned a new ground-mounted photovoltaic system at its Neuland site in Switzerland. The new solar power plant, with a capacity of 1,200 kWp, comprises 2,448 photovoltaic modules installed on an area of approximately 6,200 m². This development underscores the company's commitment to sustainability and the expansion of renewable energy within its operations.

The facility is designed to be one of the most efficient conventional ground-mounted systems in the Swiss Mittelland region. Ground-mounted photovoltaic systems remain rare in Switzerland, making this a significant installation for an industrial site. The energy generated will be used primarily for on-site consumption, which is expected to sustainably reduce the company's CO2 emissions.

Project Details and Implementation

The project was executed in collaboration with energy and infrastructure partners IWB (Industrielle Werke Basel) and its subsidiary Planeco. These partners were responsible for the planning and implementation of the facility. The construction phase lasted three months, concluding with an official opening ceremony attended by government officials and company representatives.

Strategic Impact

Stephan Fritschi, Chief Executive Officer of CARBOGEN AMCIS, stated that the commissioning represents a targeted investment in a sustainable energy supply. The project is viewed as an important milestone in the company's path to implementing environmental goals. CARBOGEN AMCIS aims to continuously improve energy efficiency and increase the share of renewable energy in its production processes.

CARBOGEN AMCIS is a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company. It is a wholly owned subsidiary of Dishman Carbogen Amcis Ltd .